A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Memgen, LLC.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
The Leukemia and Lymphoma Society
Information provided by:
Memgen, LLC
ClinicalTrials.gov Identifier:
NCT00772486
First received: October 14, 2008
Last updated: November 18, 2010
Last verified: November 2010
  Purpose

The study is a Phase 1b open label, non-randomized, single institution clinical trial that is designed to evaluate the safety and tolerability of three repeat infusions of ISF35 followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) in subjects with refractory, resistant, and/or 17p- CLL.


Condition Intervention Phase
Chronic Lymphocytic Leukemia
Biological: ISF35
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1b Study of Repeated Doses of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Combination With Fludarabine, Cyclophosphamide and Rituximab (FCR) in Subjects With Chronic Lymphocytic Leukemia (CLL)

Resource links provided by NLM:


Further study details as provided by Memgen, LLC:

Primary Outcome Measures:
  • Assess toxicity, tolerability, and safety of repeat administration of three infusions of 3x10^8 ISF35 given intravenously in combination with a standard course of three treatments of fludarabine, rituximab and cyclophosphamide (FCR). [ Time Frame: Duration of the Trial ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Explore the anti-leukemia activity of the repeat administration of ISF35 and FCR by evaluating reduction in leukemia count, reduction in lymphadenopathy and splenomegaly, improvement in bone marrow function, and response duration. [ Time Frame: Duration of the Trial ] [ Designated as safety issue: No ]
  • Assess induction of B and T cell anti-leukemia immune responses, antibody production against autologous CLL B cells, changes in bystander leukemia cell phenotype, and expression of genes and proteins related to apoptosis [ Time Frame: Duration of the Trial ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: September 2008
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: ISF35
    Subjects participating in this study will receive a course of three infusions of 3x10^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
    Other Names:
    • Ad-ISF35
    • ISF35
    • AdISF35
Detailed Description:

ISF35 has already been used in two Phase I clinical trials. The trials demonstrated that ISF35 treatment is well tolerated and patients did not experience any significant or unexpected adverse events. Patients reported flu-like symptoms from ISF35, which disappeared within one to three days.

The trials also showed that ISF35 stimulates the immune system to act against CLL cells and sensitize leukemic cells to subsequent treatment. Repeat infusions of ISF35 administered as a single agent to subjects with CLL resulted in durable reductions in circulating and lymph-node bound leukemic cells. Furthermore, CLL patients with 17p deletion responded to standard courses of FCR after receiving ISF35 and achieved durable remissions.

ISF35 is an abbreviation for Immune Stimulatory Factor 35, an offspring of technology discovered by Dr. Thomas J. Kipps, MD, PhD, Professor, Department of Medicine and Deputy Director for Research,UCSD Moores Cancer Center.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Subjects must have a diagnosis of B cell CLL including:

    • Lymphocytosis of monoclonal B-cells co-expressing ≥ one B-cell marker (CD19, CD20, or CD23) and CD5 in peripheral blood or lymph node AND
    • Bone marrow with ≥ 30% mononuclear cells having the CLL/SLL phenotype
  2. Measurable disease, and at least one of the IWCLL 2008 Guidelines "Indications for Treatment" as follows:

    • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia.
    • Massive (i.e., >6 cm below the left costal margin) or progressive or asymptomatic splenomegaly.
    • Massive nodes (i.e., >10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
    • Progressive lymphocytosis with an increase of >50% over a 2-month period, or lymphocyte doubling time (LDT) of less than 6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts (ALC) obtained at intervals of two weeks over an observation period of 2-3 months; patients with initial blood lymphocyte counts of less than 30,000 per microliter may require a longer observation period to determine the LDT. Also, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g, infections) should be excluded.
    • Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids or other standard therapy.
    • A minimum of any one of the following disease-related symptoms must be present:
    • Unintentional weight loss ≥10% within the previous 6 months.
    • Significant fatigue (i.e., ECOG PS 2 or worse; cannot work or unable to perform usual activities).
    • Fevers of greater than 100.5 degrees F or 38.0 degrees C for 2 or more weeks without other evidence of infection.
    • Night sweats for more than 1 month without evidence of infection. Hypogammaglobulinemia or monoclonal or oligoclonal paraproteinemia does not by itself constitute a basis to initiate treatment.
  3. Subjects must have CLL that is documented to be resistant or refractory to standard chemotherapy regimens containing alkylating agents and/or purine analogues. Chemotherapy refractory or resistant is defined as the following:

    • CLL progression during treatment (2 cycles) with chemotherapy; OR
    • Failure to achieve a PR or CR after at least 2 cycles of chemotherapy; OR
    • No response to treatment or stable disease after at least 2 cycles of chemotherapy; OR
    • Disease progression within 6 months of treatment with chemotherapy; OR
    • CLL with cytogenetic changes documenting the loss of the short arm of chromosome 17 (17p-) associated with the loss of p53.
  4. Subjects must be age 18 years or older
  5. For men and women of child-bearing potential, use of effective barrier contraceptive methods during the study and for one month following treatment
  6. Subjects must have ECOG performance scale of ≤ 2
  7. Subjects must have adequate hematologic, renal, hepatic, and coagulation function defined as:

    • Adequate hematologic function:

    i) Platelet count ≥ 50,000/µL; AND

    ii) Hemoglobin ≥ 10 g/dL (may be supported by erythropoietin or transfusion); AND

    • Adequate renal function:

    i) Calculated creatinine clearance ≥ 30 mL/min/1.73 m^2; OR

    ii) Serum creatinine ≤ 2 times upper limit of normal; AND

    • Adequate hepatic function:

    i) Total bilirubin ≤ 2.5 times upper limit of normal; AND

    ii) ALT ≤ 2.5 times upper limit of normal; AND

    • Adequate coagulation tests:

    i) Prothrombin time international normalized ratio (INR) ≤ 1.5; AND

    ii) Partial thromboplastin time ≤ 1.5 times upper limit of normal

  8. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments

Exclusion Criteria

  1. Presence of > 55% prolymphocytes or Richter's transformation
  2. Chemotherapy (e.g., purine analogues, alkylating agents, or corticosteroids), antibody therapy, immunotherapy, radiation therapy, or participation in any investigational drug treatment within 4 weeks of enrollment into protocol or at any time during the study
  3. Ongoing toxicity from prior anti-neoplastic therapy
  4. Untreated autoimmune hemolytic anemia or immune thrombocytopenia
  5. Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis
  6. Positive serologies for HIV1,2 or HTLV I,II
  7. CMV disease with positive DNA PCR
  8. Syphilis with positive VDRL
  9. Acute Hepatitis A and C with positive serologies, and Hepatitis B, acutely or chronically infected based on CDC criteria
  10. Any illness or condition that in opinion of the investigator may affect safety of treatment or evaluation of any study's endpoints
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00772486

Locations
United States, California
University of California, San Diego Moores Cancer Center
San Diego, California, United States, 92093
Sponsors and Collaborators
Memgen, LLC
The Leukemia and Lymphoma Society
Investigators
Principal Investigator: Januario Castro, MD Assistant Clinical Professor in the Blood and Marrow Transplantation Division
  More Information

Additional Information:
Publications:
Rai KR. Characteristics and Management of Chronic Lymphocytic Leukemia. Advances in Oncology. 1996;9 No.1:17-20.
Kalil N, Cheson BD. Chronic lymphocytic leukemia. Oncologist. 1999;4:352-369.
Kay NE, Hamblin TJ, Jelinek DF, et al. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program). 2002:193-213.
Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program). 2004:163-183.
Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. New England Journal of Medicine 2005;352:804-815.
Kipps TJ. Chronic lymphocytic leukemia and related diseases. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Hematology (ed 6). New York: McGraw-Hill, Inc.; 2001:1163-1194.
Castro JE, Cantwell MJ, Prussak CE, Bole J, Wierda WG, Kipps TJ. Long-term follow up of chronic lymphocytic leukemia patients treated with CD40-ligand (CD154) gene therapy. Blood. 2003;102:Abstract 1790.

Responsible Party: Dr. Januario Castro, M.D./Assistant Clinical Professor in the Blood and Marrow Transplantation Division, University of California, San Diego Moores Cancer Center
ClinicalTrials.gov Identifier: NCT00772486     History of Changes
Obsolete Identifiers: NCT00796016
Other Study ID Numbers: CLL-35-104
Study First Received: October 14, 2008
Last Updated: November 18, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Memgen, LLC:
Chronic lymphocytic leukemia
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, B-Cell
Immune System Diseases
Rituximab
Fludarabine
Cyclophosphamide
ISF35
Ad-ISF35
Refractory
Resistant
17p-
del 17p
17p
Resistant CLL
Refractory CLL
17p- CLL
CLL

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cyclophosphamide
Fludarabine phosphate
Rituximab
Fludarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites

ClinicalTrials.gov processed this record on August 27, 2014